Podcast Summary
Becker’s Healthcare Podcast
Episode: Advancing Multi-Cancer Early Detection to Save Lives with Exact Sciences
Date: September 5, 2025
Guest: Dr. Tom Baer, Chief Medical Officer for Multi-Cancer Early Detection, Exact Sciences
Host: Lucas Vaz, Becker's Healthcare
Episode Overview
This episode explores the transformative potential of multi-cancer early detection (MCED) blood tests in healthcare. Dr. Tom Baer discusses the burden of cancer mortality, the limitations of current screening, the scientific advances behind MCED, and practical strategies for adopting this new approach within health systems. The conversation highlights Exact Sciences’ innovations and offers guidance for leaders seeking to implement these next-generation screening tools.
Key Discussion Points & Insights
1. The Need for Multi-Cancer Early Detection
Timestamps: [01:50] – [04:53]
- Cancer Statistics:
- Over 1,700 cancer-related deaths occur daily in the U.S.
- Cancer is the second leading cause of death in the country.
- “Two thirds of those individuals are diagnosed with a cancer that we do not screen for… two thirds of cancer deaths and two thirds of cancer diagnoses are from cancer types that we essentially just allow to sneak up on us.”
— Dr. Baer [02:40]
- Current Screening Gaps:
- Only four common cancers are routinely screened in guideline-based practice.
- Many lethal cancers are detected only when symptoms emerge at advanced stages.
- Early detection is proven to save lives, offering the chance for less costly, more effective treatment with fewer side effects.
2. What is Multi-Cancer Early Detection?
Timestamps: [02:40] – [04:53]
- Concept & Promise:
- MCED tests aim to detect multiple cancer types simultaneously using a single blood test.
- These tests analyze biomarkers secreted into the bloodstream by cancer cells.
- Biomarkers include circulating DNA methylation and tumor-associated proteins (as featured in Exact Sciences’ approach).
- “Multi cancer early detection is all about changing that reality…”
— Dr. Baer [02:40] - Expands the reach of screening “to the large majority of cancers that we’re at risk for.”
— Dr. Baer
- Potential Impact:
- Dramatic shift toward diagnosing cancers at earlier stages, increasing the potential for cure.
3. Engaging Health System Leaders: The Survey Initiative
Timestamps: [04:53] – [06:22]
- Learning from Health Systems:
- Exact Sciences launched a survey to understand health system leaders' attitudes, excitement, and concerns about MCED adoption.
- Goals:
- Identify perceived barriers and implementation challenges.
- Inform educational efforts and support tools.
- “We really want to understand how health system leaders view this opportunity today… what excites them the most… what barriers they see for adoption and implementation…”
— Dr. Baer [05:35]
4. Clinically-Led Implementation: Best Practices
Timestamps: [06:22] – [13:02]
- Three Key Areas of Implementation:
- Test Selection:
- Assess test features (e.g., multi-biomarker approach, early-stage sensitivity).
- Importance of detecting a broad range of cancers, especially in early stages.
- “Detecting cancer at earliest possible stages… gives us the greatest opportunity to offer a patient treatment with curative intent…”
— Dr. Baer [08:00]
- Follow-Up Pathways:
- How the test result informs a streamlined, reproducible diagnostic journey.
- MCED is a screening tool, not a diagnostic test; follow-up imaging and evaluations are essential for confirmation.
- “Like all screening tests… they deliver a signal… another additional diagnostic tests need to be conducted to rule in or rule out the presence of cancer.”
— Dr. Baer [09:12] - Exact Sciences offers navigation support for providers and patients upon positive results.
- Provider and System Readiness:
- Robust provider education about the test’s role and limitations.
- Avoiding confusion or replacement of standard-of-care screenings.
- Integrating test ordering/results into EMRs for smooth workflows.
- Ongoing outcome tracking: Monitor impact on stage distribution at diagnosis, imaging use, therapies, and long-term patient outcomes.
- Test Selection:
5. The “More Shots on Goal” Analogy
Timestamps: [13:02] – [13:29]
- Host emphasizes the importance of multiplying opportunities for early cancer detection.
- “More shots that are hitting… this is really a game-changer and can be a game-changer with more shots on goal.”
— Lucas Vaz [13:02]
6. Projected Population Impact: Modeling the Future
Timestamps: [13:29] – [15:22]
- Dr. Baer shares projections from Exact Sciences’ healthcare outcome modeling group:
- Adding annual MCED testing could shift cancer diagnosis distribution dramatically over 10 years.
- “We would expect a 42% reduction in stage 4 metastatic cancer burden across all cancer types in the population.”
— Dr. Baer [14:02] - Associated with an estimated 17–18% reduction in all-cancer mortality.
- These benefits would occur even without changes to current standard-of-care practice, assuming only the addition of annual MCED.
- “It’s these kinds of results that get me excited about working in this field every day.”
— Dr. Baer [15:16]
Notable Quotes and Memorable Moments
- “Two thirds of cancer deaths and two thirds of cancer diagnoses are from cancer types that we essentially just allow to sneak up on us.” — Dr. Baer [02:40]
- “Multi cancer early detection strives to develop blood-based cancer screening tests designed to detect many different cancers simultaneously in a single blood test.” — Dr. Baer [03:32]
- “Detecting cancer at earliest possible stages… gives us the greatest opportunity to offer a patient treatment with curative intent and long-term good outcomes.” — Dr. Baer [08:00]
- “We would expect a 42% reduction in stage 4 metastatic cancer burden… and about a 17–18% reduction in all-cancer mortality in the population.” — Dr. Baer [14:02]
- “More shots on goal... this is really a game-changer.” — Lucas Vaz [13:02]
- “It’s these kinds of results that get me excited about working in this field every day.” — Dr. Baer [15:16]
Key Timestamps
- 00:38 — Dr. Baer’s background and role at Exact Sciences
- 01:50 — Context on cancer mortality and lack of screening options
- 02:40 — What is multi-cancer early detection and its promise?
- 04:53 — Surveying health system leaders about MCED
- 06:22–13:02 — Clinically-led implementation: test selection, pathways, provider and system readiness
- 13:29–15:22 — Population modeling: projected impact of annual MCED
Summary
This episode provides an in-depth, actionable look at the promise of multi-cancer early detection tests and what their rollout at scale could mean for cancer mortality and health system delivery in the U.S. Dr. Tom Baer outlines both the scientific innovation and the practical implementation strategies required to turn MCED from a novel concept into a new standard of proactive cancer screening. The conversation bridges hope, science, and system-level challenges, with compelling data modeling and personal conviction driving the message home.